ArticleCancer imaging : the official publication of the International Cancer Imaging Society2022
Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Arterial Enhancement Fraction-Spectral CT-Based Model as Part of Prediction Model in BRAFDiagnostics (Basel, Switzerland) · 2025Article
- Dual-layer spectral detector computed tomography in distinguishing between bland and neoplastic portal vein thrombosis.Quantitative imaging in medicine and surgery · 2025Article
- Evaluation of induction chemotherapy response using multiphasic dual-energy CT in nasopharyngeal carcinoma.European radiology · 2025Article
- VETC predicting model based on CE-CT can predict prognosis and assisting treatment plan for solitary HCC: better together with radiomics.BMC cancer · 2025Article
- Dual energy CT-derived quantitative parameters and hematological characteristics predict pathological complete response in neoadjuvant chemoradiotherapy esophageal squamous cell carcinoma patients.BMC gastroenterology · 2025Article
- Pilot study of an arterial enhancement fraction-based model for progression prediction in HCC undergoing chemoembolization.Frontiers in oncology · 2025Article
- Correlation of CT parameters and PD-L1 expression status in gastric cancer.Abdominal radiology (New York) · 2024Article
- Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundArterial enhancement fraction (AEF), derived from triphasic CT scans, is considered to indirectly reflect the ratio of hepatic arterial perfusion to total perfusion. The purpose of this study was to retrospectively investigate the relationship between AEF and treatment response and survival in hepatocellular carcinoma (HCC) patients treated with drug-eluting bead (DEB) TACE.
methodsAEF of primary lesion (AEF
resultsThere was no correlation between AEF
conclusionsThe change in AEF of viable tumor is correlated with response of HCC to DEB-TACE. In addition, the AEF could be a helpful predictor in future studies on the embolization treatment for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.